Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …

Tumour cells have exquisite flexibility in reprogramming their metabolism in order to support
tumour initiation, progression, metastasis and resistance to therapies. These reprogrammed …

Accumulating evidence supports not only the functional role of the gut microbiome in cancer
development and progression but also its role in defining the efficacy and toxicity of …

Gut microbiota‐derived metabolites are key hubs connecting the gut microbiome and cancer
progression, primarily by remodeling the tumor microenvironment and regulating key …

Intestinal microbiota has its role as an important component of human physiology. It
produces metabolites that module key functions to establish a symbiotic crosstalk with their …

Immunotherapy has emerged as a robust approach against cancer, yet its efficacy has
varied among individuals, accompanied by the occurrence of immune-related adverse …

The performance of immune-checkpoint inhibitors, which benefit only a subset of patients
and can cause serious immune-related adverse events, underscores the need for strategies …

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer-related death worldwide. It involves the complex interactions between genetic …

The human gut microbiota is a complex ecosystem involved in the metabolism, immunity,
and health of the host. The microbiome plays a key role in the development of the host's …

The gut microbiota modulates immune processes both locally and systemically. This
includes whether and how the immune system reacts to emerging tumours, whether …